ABSTRACT
As the master regulator of the intrauterine environment, the placenta is core to the Developmental Origins of Health and Disease (DOHaD) but is understudied in relation to tissue-specific gene and trait regulation. We performed distal mediator-enriched transcriptome-wide association studies (TWAS) for 40 health traits across 5 physiological categories, using gene expression models trained with multi-omic data from the Extremely Low Gestational Age Newborn Study (N = 272). At P < 2.5 × 10−6, we detected 248 gene-trait associations (GTAs) across 176 genes, mostly for metabolic and neonatal traits and enriched for cell growth and immunological pathways. Of these GTAs, 89 showed significant mediation through genetic variants distal to the gene, identifying potential targets for functional validation. Functional validation of a mediator gene (EPS15) in human placenta-derived JEG-3 trophoblasts resulted in increased expression of its predicted targets, SPATA13 and FAM214A, both associated with the trait of waist-hip ratio in TWAS. These results illustrate the profound health impacts of placental genetic and genomic regulation in developmental programming across the life course.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (U01NS040069; R01NS040069), the Office of the NIH Director (UG3OD023348), the National Institute of Environmental Health Sciences (T32-ES007018; P30ES019776; R24ES028597), the National Institute of Nursing Research (K23NR017898; R01NR019245), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD092374; R03HD101413; P50HD103573). The funders had no role in study design or analysis.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of the University of North Carolina at Chapel Hill. All participants consented to the study as per IRB protocol.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
ELGAN mRNA, miRNA, and CpG methylation data can be accessed from the NCBI Gene Expression Omnibus GSE154829 and GSE167885. ELGAN genotype data is protected, as subjects are still enrolled in the study; any inquiries or data requests must be made to RCF and HPS. All models and full TWAS results are found at https://doi.org/10.5281/zenodo.461803699.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE154829
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167885
http://www.nealelab.is/uk-biobank
https://portals.broadinstitute.org/collaboration/giant/index.php/Main_Page
https://www.med.unc.edu/pgc/download-results/
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001586.v1.p1
